Tacrolimus (FK506): Safety and applications in reconstructive surgery

Hand

Volumn 5, Issue 1, 2010, Pages 1-8

  Tung, Thomas H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Clinical trials; FK506; Nerve; Nerve injury; Nerve regeneration; Rheumatoid arthritis; Safety; Tacrolimus; Transplantation

Indexed keywords

EID: 76649135159     PISSN: 15589447     EISSN: 15589455     Source Type: Journal    
DOI: 10.1007/s11552-009-9193-8     Document Type: Review

References (105)

1. Prescribing information for Prograf; Physician's Desk Reference. Montvale, NJ, Medical Economics Co. pp 1393-1397.
2. Akimoto K, Kusunoki Y, Nishio S, Takagi K, Kawai S. Safety profile of tacrolimus in patients with rheumatoid arthritis. Clin Rheumatol. 2008; 27: 1393-7. doi: 10. 1007/s10067-008-0931-z.
3. Archibald SJ, Shefner J, Krarup C, Madison RD. Monkey median nerve repaired by nerve graft or collagen nerve guide tube. J Neurosci. 1995; 15: 4109-23.
4. Archibald SJ, Wang MS, Gold BG. FK506 accelerates axonal regeneration through an artificial nerve guide in the rat sciatic nerve transection model. J Peripher Nerv Syst. 1999; 4: 202.
5. Avramut M, Achim CL. Immunophilins in nervous system degeneration and regeneration. Curr Top Med Chem. 2003; 3: 1376-82. doi: 10. 2174/1568026033451871.
6. Baumgart DC, Macdonald JK, Feagan B (2008) Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev CD007216.
7. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol. 2006; 101: 1048-56. doi: 10. 1111/j. 1572-0241. 2006. 00524. x.
8. Bavetta S, Hamlyn PJ, Burnstock G, Lieberman AR, Anderson PN. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: neuroprotection and local regeneration. Exp Neurol. 1999; 158: 382-93. doi: 10. 1006/exnr. 1999. 7119.
9. Becker DB, Jensen JN, Myckatyn TM, Doolabh VB, Hunter DA, Mackinnon SE. Effects of FKBP-12 ligands following tibial nerve injury in rats. J Reconstr Microsurg. 2000; 16: 613-20. doi: 10. 1055/s-2000-9379.
10. Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis. 2008; 14: 7-12. doi: 10. 1002/ibd. 20263.
11. Birge RB, Wadsworth S, Akakura R, Abeysinghe H, Kanojia R, MacIelag M, et al. A role for Schwann cells in the neuroregenerative effects of a non-immunosuppressive fk506 derivative, jnj460. Neuroscience. 2004; 124: 351-66. doi: 10. 1016/j. neuroscience. 2003. 10. 013.
12. Brenner MJ, Tung TH, Jensen JN, Mackinnon SE (2002) The spectrum of complications of immunosuppression: is the time right for hand transplantation? J Bone Joint Surg Am 84-A: 1861-70.
13. Bronster DJ, Emre S, Mor E, Sheiner P, Miller CM, Schwartz ME (1994) Neurologic complications of orthotopic liver transplantation. Mt Sinai J Med 61: 63-9. Review. 66 refs.
14. Chen GF, Gu LQ, Pei GX (2002) Peripheral nerve regeneration under immunosuppression. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 16: 139-41.
15. Chunasuwankul R, Ayrout C, Dereli Z, Gal A, Lanzetta M, Owen E. Low dose discontinued FK506 treatment enhances peripheral nerve regeneration. Int Surg. 2002; 87: 274-8.
16. Chung S, Park CW, Song J, Kim JA, Shin SJ, Chang YS. Simultaneous and sustained remission of intractable myasthenia gravis and focal segmental glomerulosclerosis with tacrolimus treatment. Clin Nephrol. 2008; 70: 59-61.
17. Costa A, Alessiani M, De Ponti F, Spada M, Merli M, Zanola S, et al. Stimulatory effect of FK506 and erythromycin on pig intestinal motility. Transplant Proc. 1996; 28: 2571-2.
18. Costantini LC, Chaturvedi P, Armistead DM, McCaffrey PG, Deacon TW, Isacson O. A novel immunophilin ligand: distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease. Neurobiol Dis. 1998; 5: 97-106. doi: 10. 1006/nbdi. 1998. 0185.
19. Cronin DC, Faust TW, Brady L, Conjeevaram H, Jain S, Gupta P, Millis JM (2000) Modern immunosuppression. Clin Liver Dis 4: 619-55. Review. 220 refs. doi: 10. 1016/S1089-3261(05)70130-6.
20. Curran MP, Perry CM. Tacrolimus: in patients with rheumatoid arthritis. Drugs. 2005; 65: 993-1001. doi: 10. 2165/00003495-200565070-00005.
21. Doolabh VB, Mackinnon SE. FK506 accelerates functional recovery following nerve grafting in a rat model. Plast Reconstr Surg. 1999; 103: 1928-36. doi: 10. 1097/00006534-199906000-00018.
22. Dubernard JM, Owen E, Herzberg G, Lanzetta M, Martin X, Kapila H, et al. Human hand allograft: report on first 6 months. Lancet. 1999; 353: 1315-20. doi: 10. 1016/S0140-6736(99)02062-0.
23. Dubernard JM, Owen E, Herzberg G, Martin X, Guigal V, Dawahra M, et al. The first transplantation of a hand in humans. Early results. Chirurgie. 1999; 124: 358-65. doi: 10. 1016/S0001-4001(00)80007-0.
24. Dubernard JM, Petruzzo P, Lanzetta M, Parmentier H, Martin X, Dawahra M, et al. Functional results of the first human double-hand transplantation. Ann Surg. 2003; 238: 128-36. doi: 10. 1097/00000658-200307000-00017.
25. Emborg ME, Shin P, Roitberg B, Sramek JG, Chu Y, Stebbins GT, et al. Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp Neurol. 2001; 168: 171-82. doi: 10. 1006/exnr. 2000. 7592.
26. Fansa H, Keilhoff G, Altmann S, Plogmeier K, Wolf G, Schneider W (1999) The effect of the immunosuppressant FK 506 on peripheral nerve regeneration following nerve grafting. J Hand Surg [Br] 24: 38-42. doi: 10. 1016/S0266-7681(99)90021-9.
27. Fansa H, Keilhoff G, Horn T, Altmann S, Wolf G, Schneider W. Stimulation of Schwann cell growth and axon regeneration of peripheral nerves by the immunosuppressive drug FK 506. Handchir Mikrochir Plast Chir. 1999; 31: 323-9. doi: 10. 1055/s-1999-13544.
28. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. 2002; 46: 2020-8. doi: 10. 1002/art. 10427.
29. Gold BG. FK506 and the role of immunophilins in nerve regeneration. Mol Neurobiol. 1997; 15: 285-306. doi: 10. 1007/BF02740664.
30. Gold BG. Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opin Investig Drugs. 2000; 9: 2331-42. doi: 10. 1517/13543784. 9. 10. 2331.
31. Gold BG, Densmore V, Shou W, Matzuk MM, Gordon HS. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. J Pharmacol Exp Ther. 1999; 289: 1202-10.
32. Gold BG, Gordon HS, Wang MS. Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: lack of evidence for a conditioning lesion-like effect. Neurosci Lett. 1999; 267: 33-6. doi: 10. 1016/S0304-3940(99)00333-X.
33. Gold BG, Katoh K, Storm-Dickerson T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J Neurosci. 1995; 15: 7509-16.
34. Gold BG, Storm-Dickerson T, Austin DR. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury. Restor Neurol Neurosci. 1994; 6: 287-96.
35. Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics. 2008; 5: 535-41. doi: 10. 1016/j. nurt. 2008. 08. 011.
36. Guimberteau JC, Baudet J, Panconi B, Boileau R, Potaux L. Human allotransplant of a digital flexion system vascularized on the ulnar pedicle: a preliminary report and 1-year follow-up of two cases. Plast Reconstr Surg. 1992; 89: 1135-47. doi: 10. 1097/00006534-199206000-00023.
37. Guo X, Dawson VL, Dawson TM. Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur J Neurosci. 2001; 13: 1683-93. doi: 10. 1046/j. 0953-816x. 2001. 01542. x.
38. Guo X, Dillman JF III, Dawson VL, Dawson TM. Neuroimmunophilins: novel neuroprotective and neuroregenerative targets. Ann Neurol. 2001; 50: 6-16. doi: 10. 1002/ana. 1030.
39. Hart IK, Sharshar T, Sathasivam S. Immunosuppressant drugs for myasthenia gravis. J Neurol Neurosurg Psychiatry. 2009; 80: 5-6. doi: 10. 1136/jnnp. 2008. 144980.
40. Hassan J, van der Net JJ, Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol. 2008; 27: 1469-71. doi: 10. 1007/s10067-008-0973-2.
41. Hoekstra HJ, Hawkins K, de Boer WJ, Rottier K, van der BW. Gastrointestinal complications in lung transplant survivors that require surgical intervention. Br J Surg. 2001; 88: 433-8. doi: 10. 1046/j. 1365-2168. 2001. 01693. x.
42. Hofmann GO, Kirschner MH, Brauns L, Wagner FD, Land W, Buhren V. Vascularized knee joint transplantation in man: a report on the first cases. Transpl Int. 1998; 11(Suppl 1): S487-90.
43. Hofmann GO, Kirschner MH, Wagner FD, Brauns L, Gonschorek O, Buhren V. Allogeneic vascularized transplantation of human femoral diaphyses and total knee joints-first clinical experiences. Transplant Proc. 1998; 30: 2754-61. doi: 10. 1016/S0041-1345(98)00803-3.
44. Ishigaki K, Shishikura K, Murakami T, Suzuki H, Hirayama Y, Osawa M Benefits of FK 506 for refractory eye symptoms in a young child with ocular myasthenia gravis. Brain Dev. 2008. doi: 10. 1016/j. braindev. 2008. 08. 016.
45. Itoh Z, Nakaya M, Suzuki T, Arai H, Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am J Physiol. 1984; 247: G688-94.
46. Itoh Z, Suzuki T, Nakaya M, Inoue M, Arai H, Wakabayashi K. Structure-activity relation among macrolide antibiotics in initiation of interdigestive migrating contractions in the canine gastrointestinal tract. Am J Physiol. 1985; 248: G320-5.
47. Itoh Z, Suzuki T, Nakaya M, Inoue M, Mitsuhashi S. Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrob Agents Chemother. 1984; 26: 863-9.
48. Jap A, Chee SP. Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol. 2008; 19: 535-40. doi: 10. 1097/ICU. 0b013e3283126d20.
49. Jones JW, Gruber SA, Barker JH, Breidenbach WC. Successful hand transplantation: one-year follow-up. N Engl J Med. 2000; 343: 468-73. doi: 10. 1056/NEJM200008173430704.
50. Jost SC, Doolabh VB, Mackinnon SE, Lee M, Hunter D. Acceleration of peripheral nerve regeneration following FK506 administration. Restor Neurol Neurosci. 2000; 17: 39-44.
51. Kawai S, Hashimoto H, Kondo H, Murayama T, Kiuchi T, Abe T. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol. 2006; 33: 2153-61.
52. Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol. 2004; 31: 243-51.
53. Kwok BW, Hunt SA (2000) Neoplasia after heart transplantation. Cardiol Rev 8: 256-9. Review. 24 refs. doi: 10. 1097/00045415-200008050-00004.
54. Lee M, Doolabh VB, Mackinnon SE, Jost S. FK506 promotes functional recovery in crushed rat sciatic nerve. Muscle Nerve. 2000; 23: 633-40. doi: 10. 1002/(SICI)1097-4598(200004)23: 4< 633:: AID-MUS24> 3. 0. CO; 2-Q.
55. Mackinnon SE, Doolabh VB, Novak CB, Trulock EP. Clinical outcome following nerve allograft transplantation. Plast Reconstr Surg. 2001; 107: 1419-29. doi: 10. 1097/00006534-200105000-00016.
56. Mackinnon SE, Hudson AR. Clinical application of peripheral nerve transplantation. Plast Reconstr Surg. 1992; 90: 695-9. doi: 10. 1097/00006534-199210000-00024.
57. Madsen JR, MacDonald P, Irwin N, Goldberg DE, Yao GL, Meiri KF, et al. Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats. Exp Neurol. 1998; 154: 673-83. doi: 10. 1006/exnr. 1998. 6974.
58. Maes BD, Vanwalleghem J, Kuypers D, Ghoos Y, Rutgeerts PJ, Vanrenterghem YF. Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. Transplantation. 1999; 68: 1482-5. doi: 10. 1097/00007890-199911270-00009.
59. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet. 2002; 359: 741-6. doi: 10. 1016/S0140-6736(02)07875-3.
60. Margreiter R, Brandacher G, Ninkovic M, Steurer W, Kreczy A, Schneeberger S. A double-hand transplant can be worth the effort!. Transplantation. 2002; 74: 85-90. doi: 10. 1097/00007890-200207150-00015.
61. Martin D, Pinsolle V, Merville P, Moreau K, Pelissier P, Baudet J. First case in the world of autoreplantation of a limb associated with oral administration of an immunosupressant agent (FK 506-Tacrolimus). Ann Chir Plast Esthet. 2005; 50: 257-63. doi: 10. 1016/j. anplas. 2005. 02. 001.
62. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation. 1997; 64: 436-43. doi: 10. 1097/00007890-199708150-00012.
63. Mor E, Schwersenz A, Sheiner PA, Emre S, Schwartz ME, Miller CM. Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. Transplantation. 1994; 57: 1130-2. doi: 10. 1097/00007890-199404150-00025.
64. Morita Y, Sasae Y, Sakuta T, Satoh M, Sasaki T, Kashihara N. Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study. Mod Rheumatol. 2008; 18: 379-84. doi: 10. 1007/s10165-008-0071-y.
65. Myckatyn TM, Ellis RA, Grand AG, Sen SK, Lowe JB III, Hunter DA, et al. The effects of rapamycin in murine peripheral nerve isografts and allografts. Plast Reconstr Surg. 2002; 109: 2405-17. doi: 10. 1097/00006534-200206000-00035.
66. Nagaishi A, Yukitake M, Kuroda Y. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus. Intern Med. 2008; 47: 731-6. doi: 10. 2169/internalmedicine. 47. 0513.
67. Naniwa T, Watanabe M, Banno S, Maeda T Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies. Rheumatol. Int. 2009 (in press).
68. Navarro X, Udina E, Ceballos D, Gold BG. Effects of FK506 on nerve regeneration and reinnervation after graft or tube repair of long nerve gaps. Muscle Nerve. 2001; 24: 905-15. doi: 10. 1002/mus. 1088.
69. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 129-34. doi: 10. 1002/ibd. 20052.
70. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006; 55: 1255-62. doi: 10. 1136/gut. 2005. 081794.
71. Okan G, Yaylaci S, Peker O, Kaymakoglu S, Saruc M. Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus. World J Gastroenterol. 2008; 14: 4697-700. doi: 10. 3748/wjg. 14. 4697.
72. Otley CC, Pittelkow MR (2000) Skin cancer in liver transplant recipients. Liver Transpl 6: 253-62. Review. 53 refs.
73. Pan YA, Misgeld T, Lichtman JW, Sanes JR. Effects of neurotoxic and neuroprotective agents on peripheral nerve regeneration assayed by time-lapse imaging in vivo. J Neurosci. 2003; 23: 11479-88.
74. Pei G, Gu L, Yu L. A preliminary report of two cases of human hand allograft. Zhonghua Yi Xue Za Zhi. 2000; 80: 417-21.
75. Penn I (2000) Post-transplant malignancy: the role of immunosuppression. Drug Saf 23: 101-13. Review. 71 refs. doi: 10. 2165/00002018-200023020-00002.
76. Porter GA, Bennett WM, Sheps SG. Cyclosporine-associated hypertension. Arch Intern Med. 1990; 150: 280-3. doi: 10. 1001/archinte. 150. 2. 280.
77. Preiksaitis JK, Keay S (2001) Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis 33(Suppl 1): S38-46. Review. 104 refs. doi: 10. 1086/320903.
78. Revill WP, Voda J, Reeves CR, Chung L, Schirmer A, Ashley G, et al. Genetically engineered analogs of ascomycin for nerve regeneration. J Pharmacol Exp Ther. 2002; 302: 1278-85. doi: 10. 1124/jpet. 102. 034264.
79. Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol. 2008; 4: 317-27. doi: 10. 1038/ncpneuro0810.
80. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003; 63: 1247-97. doi: 10. 2165/00003495-200363120-00006.
81. Snydman DR (2001) Epidemiology of infections after solid-organ transplantation. Clin Infect Dis 33(Suppl 1): S5-8. Review. 40 refs. doi: 10. 1086/320897.
82. Sosa I, Reyes O, Kuffler DP. Immunosuppressants: neuroprotection and promoting neurological recovery following peripheral nerve and spinal cord lesions. Exp Neurol. 2005; 195: 7-15. doi: 10. 1016/j. expneurol. 2005. 04. 016.
83. Strome M, Stein J, Esclamado R, Hicks D, Lorenz RR, Braun W, et al. Laryngeal transplantation and 40-month follow-up. N Engl J Med. 2001; 344: 1676-9. doi: 10. 1056/NEJM200105313442204.
84. Sugawara T, Itoh Y, Mizoi K. Immunosuppressants promote adult dorsal root regeneration into the spinal cord. Neuroreport. 1999; 10: 3949-53. doi: 10. 1097/00001756-199912160-00041.
85. Sulaiman OA, Voda J, Gold BG, Gordon T. FK506 increases peripheral nerve regeneration after chronic axotomy but not after chronic Schwann cell denervation. Exp Neurol. 2002; 175: 127-37. doi: 10. 1006/exnr. 2002. 7878.
86. Suzuki K, Kameda H, Amano K, Nagasawa H, Takei H, Sekiguchi N, et al. Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. Rheumatol Int. 2009; 29: 431-6. doi: 10. 1007/s00296-008-0833-z.
87. Szeto CC, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008; 47: 1678-81. doi: 10. 1093/rheumatology/ken335.
88. Tamaki H, Nakase H, Matsuura M, Inoue S, Mikami S, Ueno S, et al. The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn's disease. J Gastroenterol. 2008; 43: 774-9. doi: 10. 1007/s00535-008-2229-y.
89. The US. Multicenter FK506 Liver Study Group: a comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 2004; 331: 1110-5.
90. Udina E, Ceballos D, Gold BG, Navarro X. FK506 enhances reinnervation by regeneration and by collateral sprouting of peripheral nerve fibers. Exp Neurol. 2003; 183: 220-31. doi: 10. 1016/S0014-4886(03)00173-0.
91. Udina E, Navarro X. Immunophilins: neuroprotective agents and promoters of neural regeneration. Neurologia. 2002; 17: 200-13. doi: 10. 1159/000059370.
92. Udina E, Voda J, Gold BG, Navarro X. Comparative dose-dependence study of FK506 on transected mouse sciatic nerve repaired by allograft or xenograft. J Peripher Nerv Syst. 2003; 8: 145-54. doi: 10. 1046/j. 1529-8027. 2003. 03020. x.
93. Wang MS, Gold BG. FK506 increases the regeneration of spinal cord axons in a predegenerated peripheral nerve autograft. J Spinal Cord Med. 1999; 22: 287-96.
94. Wang MS, Zeleny-Pooley M, Gold BG. Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve. J Pharmacol Exp Ther. 1997; 282: 1084-93.
95. Woolfson RG, Neild GH (1997) Cyclosporin nephrotoxicity following cardiac transplantation. Nephrol Dial Transplant 12: 2054-6. Review. 26 refs. doi: 10. 1093/ndt/12. 10. 2054.
96. Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008; 28: 589-97. doi: 10. 1111/j. 1365-2036. 2008. 03764. x.
97. Yamani MH, Starling RC (2000) Long-term medical complications of heart transplantation: information for the primary care physician. Cleve Clin J Med 67: 673-80. Review. 48 refs.
98. Yang RK, Lowe JB III, Sobol JB, Sen SK, Hunter DA, Mackinnon SE. Dose-dependent effects of FK506 on neuroregeneration in a rat model. Plast Reconstr Surg. 2003; 112: 1832-40. doi: 10. 1097/01. PRS. 0000091167. 27303. 18.
99. Yildirim FB, Sarikcioglu L, Ozsoy U, Demir N, Demirtop A, Ucar Y. Effect of FK506 administration after obturator nerve injury: a functional and ultrastructural study. Acta Neurobiol Exp (Warsz). 2008; 68: 477-83.
100. Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle-Gaw LJ, et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford). 2004; 43: 992-9. doi: 10. 1093/rheumatology/keh155.
101. Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum. 2003; 48: 3328-37. doi: 10. 1002/art. 11363.
102. Yokota K, Akiyama Y, Asanuma Y, Miyoshi F, Sato K, Mimura T. Efficacy of tacrolimus in infliximab-refractory progressive rheumatoid arthritis. Rheumatol Int. 2009; 29: 459-61. doi: 10. 1007/s00296-008-0694-5.
103. Yoshida S, Kotani T, Takeuchi T, Isoda K, Hata K, Watanabe K, et al. Successful treatment of early intervention with tacrolimus for a patient with lupus nephritis III + V. Nihon Rinsho Meneki Gakkai Kaishi. 2008; 31: 460-4. doi: 10. 2177/jsci. 31. 460.
104. Zietse R, Balk AH, Dorpel MA vd, Meeter K, Bose E, Weimar W. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol. 1994; 14: 1-5. doi: 10. 1159/000168677.
105. Ziring DA, Wu SS, Mow WS, Martin MG, Mehra M, Ament ME. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr. 2007; 45: 306-11.